吉西他滨联合顺铂动、静脉化疗治疗晚期非小细胞肺癌的疗效观察  

Efficacy of Gemcitabine Combined with Cisplatin Arterial and Intravenous Chemotherapy for Advanced Non-small Cell Lung Cancer

作　　者：李艳丽[1] 刘鹏辉[1] 赵冠人[1] 

机构地区：[1]解放军第309医院,100091

出　　处：《实用癌症杂志》2015年第12期1846-1848,1851,共4页The Practical Journal of Cancer

摘　　要：目的探讨吉西他滨联合顺铂动、静脉联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效与安全性。方法按照随机数字表的分组方法将136例患者分为对照组和观察组,各68例。对照组给予注射用盐酸吉西他滨1 000 mg/m2、顺铂注射液50 mg/m2静脉滴注化疗治疗。观察组于第1天经支气管动脉药物灌注吉西他滨1 000 mg/m2+顺铂50mg/m2,于第8天再次给予吉西他滨1 000 mg/m2静脉滴注化疗治疗。分析2组近期治疗总有效率、生活质量改善情况及不良反应。结果观察组近期治疗总有效率高于对照组,2组差异有统计学意义(P<0.05)。观察组中鳞癌及中央型肺癌患者的临床治疗有效率分别高于腺癌及周围型肺癌患者,2组差异均有统计学意义(P均<0.05)。观察组生活质量改善率高于对照组,且与对照组比较,差异有统计学意义(P<0.05)。2组不良反应发生率经统计学比较,差异无统计学意义(P>0.05)。结论吉西他滨、顺铂动、静脉联合化疗治疗晚期NSCLC患者,可提高患者的临床治疗有效率,改善患者的生活质量,具有较高的安全性。Objective To investigate the efficacy and safety of gemcitabine combined with cisplatin arterial and intrave-nous chemotherapy for advanced non-small cell lung cancer （NSCLC）.Methods 133 patients were randomly divided into the control group and the observation group,68 cases in each.The control group were treated with gemcitabine（1 000 mg/m^2 ） and cisplatin（50 mg/m^2）.And the observation group were treated with gemcitabine（1 000 mg/m^2） and cisplatin（50 mg/m^2） through bronchial artery infusion at the first day,and then were given gemcitabine（1 000 mg/m^2 ） at the 8th day through intrave-nous.The total effective rate of recent treatment,improvement rate of quality life and adverse reactions of the 2 groups were com-pared.Results The total effective rate in the observation group was significantly higher than that of the control group,the differ-ence was statistically significant （P〈0.05）.In the observation group,the total effective rate in patients with squamous cell carci-noma and central type lung cancer were higher than those of patients with adenocarcinoma and peripheral lung cancer（ both P〈0.05）.The quality life improvement rate in the observation group was higher than that of the control group（P〈0.05）.The inci-dence of adverse reactions in the 2 groups had no statistically significant difference（P〉0.05）.Conclusion Gemcitabine com-bined with cisplatin arterial and intravenous chemotherapy for advanced NSCLC can improve the clinical efficiency,quality of life and has high security.

关 键 词：肺癌 晚期 吉西他滨 顺铂 经支气管动脉药物灌注 疗效 

分 类 号：R734.2[医药卫生—肿瘤]